plasma l-carnitine levels in subjects undergoing cardiac evaluation (n = 2,595) predict increased risks for both prevalent cardiovascular disease (cvd) and incident major adverse cardiac events (mi, stroke or death), but only among subjects with concurrently high tmao levels.